NNC0385-0434
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk
Conditions
Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers
Trial Timeline
Dec 9, 2021 → May 31, 2022
NCT ID
NCT05091073About NNC0385-0434
NNC0385-0434 is a phase 1 stage product being developed by Novo Nordisk for Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk. The current trial status is completed. This product is registered under clinical trial identifier NCT05091073. Target conditions include Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05091073 | Phase 1 | Completed |
Competing Products
2 competing products in Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Niacin/simvastatin compared to simvastatin alone at 2 doses | Merck | Approved | 85 |
| TQJ230 + Placebo | Novartis | Phase 3 | 77 |